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ABSTRACT Bifidobacterium species are important commensals capable of dominat-
ing the infant gut microbiome, in part by producing acids that suppress growth of
other taxa. Bifidobacterium species are less prone to possessing antimicrobial resis-
tance (AMR) genes (ARGs) than other taxa that may colonize infants. Given that AMR
is a growing public health crisis and ARGs are present in the gut microbiome of hu-
mans from early life, this study examines the correlation between a Bifidobacterium-
dominated infant gut microbiome and AMR levels, measured by a culture-independent
metagenomic approach both in early life and as infants become toddlers. In general, Bi-
fidobacterium dominance is associated with a significant reduction in AMR in a Bangla-
deshi cohort, both in the number of acquired AMR genes present and in the abun-
dance of AMR genes. However, by year 2, Bangladeshi infants had no significant
differences in AMR related to their early-life Bifidobacterium levels. A generalized lin-
ear model including all infants in a previously published Swedish cohort found a sig-
nificant negative association between log-transformed total AMR and Bifidobacterium
levels, thus confirming the relationship between Bifidobacterium levels and AMR. In
both cohorts, there was no change between early-life and later-life AMR abundance
in high-Bifidobacterium infants but a significant reduction in AMR abundance in low-
Bifidobacterium infants. These results support the hypothesis that early Bifidobacte-
rium dominance of the infant gut microbiome may help reduce colonization by taxa
containing ARGs.
IMPORTANCE Infants are vulnerable to an array of infectious diseases, and as the
gut microbiome may serve as a reservoir of AMR for pathogens, reducing the levels
of AMR in infants is important to infant health. This study demonstrates that high
levels of Bifidobacterium are associated with reduced levels of AMR in early life and
suggests that probiotic interventions to increase infant Bifidobacterium levels have
the potential to reduce AMR in infants. However, this effect is not sustained at year
2 of age in Bangladeshi infants, underscoring the need for more detailed studies of
the biogeography and timing of infant AMR acquisition.
KEYWORDS antimicrobial resistance, bifidobacteria, gut metagenome, infant
Bifidobacterium species are key members of the infant gut microbiome, and somespecies are capable of completely dominating the breastfed infant gut (1). This
dominance of the infant gut by Bifidobacterium is linked to consumption of human milk
oligosaccharide (HMO); some species of Bifidobacterium, notably Bifidobacterium
longum subsp. infantis, consume HMO more efficiently than others (2–5). Bifidobacte-
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rium ferments HMOs into, among other products, lactate and acetate (6), which reduces
luminal pH and inhibits the growth of pathogens and other bacterial taxa in the gut (4,
5, 7). However, the proportion of infants with Bifidobacterium-dominated gut micro-
biomes appears to vary drastically between countries (8), with developing countries
such as Bangladesh (9), Malawi (10), Gambia (11), and Kenya (12) having a higher
proportion of infants with higher Bifidobacterium levels than more developed countries
such as Finland (10), Sweden (13), and the United States (14). A recent clinical trial
found that providing breastfed infants in the United States with an HMO-consuming
Bifidobacterium probiotic resulted in lasting colonization of the infant, with levels of
Bifidobacterium closer to those seen in developing countries than in the control group
(4). With the introduction of complementary feeding, natural levels of Bifidobacterium
in the infant gut decrease (15), but the influence of early-life Bifidobacterium dominance
on health extends past the period in early life to provide lasting benefit by improving
vaccine response (9), reducing risk of obesity, (16) and reducing risk of allergy (17).
This dominance of the infant gut with Bifidobacterium during early life may have
important implications for infant antimicrobial resistance (AMR) acquisition because of
the relatively low occurrence of AMR in Bifidobacterium (18, 19). While Bifidobacterium
is intrinsically resistant to several antibiotics, it is not known to carry transferable
antimicrobial resistance genes (ARGs) with the notable exception of tet(W) (18, 20).
Furthermore, there is some evidence that Bifidobacterium may reduce the transfer of
beta-lactamase resistance genes between different species of Enterobacteriaceae (21).
Therefore, a Bifidobacterium-dominated infant gut can restrict the growth of other taxa,
and the susceptibility of Bifidobacterium to antimicrobials creates the possibility that a
Bifidobacterium-dominated gut may also reduce levels of ARGs during the assembly of
the gut microbiome community as Bifidobacterium outcompetes species more prone to
AMR. This potential reduction of AMR is relevant because AMR is a substantial and
growing public health crisis both in the United States and globally. AMR can arise from
a variety of human activities, including therapeutic use of antibiotics in human and
animals and growth promotion of food-producing animals (22). The increased AMR in
the biosphere results in increased probability of transmission to humans. As AMR
becomes more common, even infants are beginning to harbor antimicrobial resistance
genes (ARGs)—ARGs have been detected in infant meconium (23). The carriage of AMR
organisms carries risks for human health; harboring AMR organisms correlates with an
increased risk of severe infection and death (24–26). This is evident at the population
level as well as the individual level. At this juncture, the AMR crisis has reached levels
such that, in the United States, AMR contributes to more than 2,000,000 illnesses and
a minimum of 23,000 deaths each year (27).
The timing of AMR acquisition by neonates and AMR persistence throughout the
first 1,000 days of life are a key health care concern. A prior study of AMR in infants not
exposed to antimicrobial agents over the 1st year of life found that erythromycin,
sulfonamide, and cefotaxime resistance were found by day 1 of life and tetracycline
resistance was detected by day 3 of life. However, the ARGs found in infants did not
always match those found in mothers (28). This same study also reported a rapid
increase in ARGs during the first few months of life (28). A twin study reported that the
infant resistome was different from the maternal resistome by 2 months of age and also
reported that resistance proteins were more likely to be found at a single time point in
an individual infant than to persist at multiple time points, suggesting that the
environment is an important source of ARGs in infants (29). Here, we examined if having
high levels of Bifidobacterium in early infancy correlated with reduced levels of AMR in
the infant gut microbiome and explored if such correlations extended into the weaning
period. To do this, this study examined the association of Bifidobacterium levels in early
life with the acquisition of AMR both when an infant may be Bifidobacterium dominated
and later in life using a cohort from a developing country (Bangladesh) with a high
prevalence of Bifidobacterium dominance of the infant gut microbiome (9) and a cohort
from a more developed country (Sweden) where Bifidobacterium dominance of the
infant gut microbiome is less common (30).
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RESULTS
Bangladeshi infants. Infant samples were selected for whole-metagenomic se-
quencing (WGS) from a prior study of vitamin A supplementation and vaccine efficacy
based on the level of Bifidobacterium present during early life (9). As part of that study,
infant stool samples were sequenced in early life (6, 11, and 15 weeks) and year 2 using
16S rRNA sequencing. This original study was then expanded to include 306 infants,
291 of whom provided at least one stool sample in early life and 249 of whom had a
year 2 stool sample sequenced (31). Of the 291 infants with at least one early-life stool
sample, 60% were delivered by Caesarean section. The relative abundance of Bifido-
bacterium in each sample was calculated using the 16S rRNA sequencing data, and
early-life samples were chosen as follows: all available low-Bifidobacterium samples
(20% Bifidobacterium relative abundance; threshold selected because the distribution
of Bifidobacterium in the cohort was bimodal, with a major peak around 80% and a
second peak under 20%) with sufficient DNA for sequencing were included. High-
Bifidobacterium samples (65% relative abundance; threshold selected because 65%
was the mean abundance of Bifidobacterium) were chosen by selecting the highest-
Bifidobacterium sample with sufficient DNA remaining for sequencing which would
maintain approximate gender balance with the low-Bifidobacterium samples (Fig. 1A
and B). To assess the stability of the Bifidobacterium groups, the Bifidobacterium levels
at week 6, 11, and 15 samples were compared in individual infants. The study (31)
included 287 infants with multiple early-life samples. Of these infants, 42% (121 infants)
of infants had a stable colonization pattern: 35% (101 infants) had samples included in
the high-Bifidobacterium group at all sequenced time points, 6% (17 infants) had
samples that consistently fell in the intermediate-Bifidobacterium group, and 1% (3
infants) had samples that were classified as low Bifidobacterium at all time points. In
addition, 22% of infants (63 infants) transitioned from a lower level of Bifidobacterium
to a higher level: 17% (50 infants) transitioned from the intermediate group at the
earliest time point to the high group, 2% (5 infants) transitioned from the low-
Bifidobacterium group to the intermediate group, and 3% (8 infants) transitioned from
the low group at the earliest time point to the high group at the last time point.
Seventeen percent of infants (48 infants) showed decreased Bifidobacterium over time:
15% (42 infants) transitioned from the high group to the intermediate group, 1% (2
infants) transitioned from the high group to the low group, and 1% (4 infants)
transitioned from the intermediate group to the low group. Sixteen percent of infants
(45 infants) fluctuated between two categories: 13% (37 infants) fluctuated between
the high and intermediate groups, 2% (5 infants) fluctuated between the low and
intermediate groups, and 1% (3 infants) fluctuated between the low and high groups.
The remaining 3% of infants had 1 sample in each of the three categories. Volatility is
a normal feature of the infant gut microbiome (32), and as such, some fluctuation
between Bifidobacterium groups over time is anticipated. The greater stability of infants
with high levels of Bifidobacterium is consistent with the literature, which shows that
infants given a Bifidobacterium longum subsp. infantis probiotic in the 1st week of life
tend to have greater stability of the microbiome than infants who received the placebo
(5). Furthermore, the high levels of Bifidobacterium circulating in this population likely
provide ample opportunity for infants to acquire Bifidobacterium at later ages, perhaps
explaining why 22% of infants transitioned to higher levels of Bifidobacterium at a later
time point. To avoid repeated-measure issues in the whole-metagenomic sequencing,
only one early-life sample per infant was eligible for inclusion. For infants with multiple
low-Bifidobacterium samples available, a sample was chosen at random for inclusion.
For high-Bifidobacterium samples, the sample with the highest relative abundance of
Bifidobacterium that would maintain close to gender parity with the low-Bifidobacterium
samples was selected. The high prevalence of Bifidobacterium colonization in the
Bangladeshi infants limited the number of infants with samples that met the criteria of
low Bifidobacterium (20% relative abundance of Bifidobacterium). As a result, all
samples that met the criteria for low Bifidobacterium and had sufficient DNA for WGS
Early-Life Bifidobacteria and Antimicrobial Resistance
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were included (a total of 13 samples). These low-Bifidobacterium samples included one
sample from each of the 3 infants who exhibited stable low-Bifidobacterium relative
abundance, 4 samples from infants who initially had low Bifidobacterium levels and later
had high Bifidobacterium levels, 2 samples from infants who transitioned from the
low-Bifidobacterium group to the intermediate group, 3 samples from infants who
fluctuated between the low and intermediate groups, and a single sample from an
infant who had samples in each of the three categories. For high Bifidobacterium, 18
early-life high-Bifidobacterium (65% relative abundance of Bifidobacterium) samples
were sequenced. The majority of the included high-Bifidobacterium samples (13 sam-
ples) were from infants with a stable high-colonization pattern, with 3 samples coming
from infants who fluctuated between the high-Bifidobacterium and intermediate cate-
gories and 2 samples coming from infants who transitioned from the high group to the
FIG 1 Relative abundance of Bifidobacterium in early-life Bangladeshi samples. (A) Relative abundance of Bifidobacterium in all early-life samples from
Bangladesh by 16S rRNA gene sequencing, up to three samples per infant included. Of 849 samples, 550 samples were high Bifidobacterium and 53 samples
were low Bifidobacterium. (B) Relative abundance of Bifidobacterium in early-life samples included in AMR analysis by 16S rRNA gene sequencing, only one
sample per infant included. (C) Relative abundance of Bifidobacterium in early-life samples included in AMR analysis using WGS data as analyzed by METAXA2;
samples are in the same order as in panel B. (D) Relative abundance of Bifidobacterium at year 2. No year 2 sample had high-enough Bifidobacterium levels to
be classified as high Bifidobacterium.
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intermediate group at later time points. This resulted in a total of 31 early-life infant
samples for inclusion. Of these 31 infants, 15 infants had a year 2 sample with sufficient
DNA available for WGS. High- and low-Bifidobacterium infants were similar in gender
and week of early-life sample collection (Table 1). METAXA2 v. 2.1.3 was used to confirm
the relative abundance of Bifidobacterium in the early-life samples (Fig. 1C). As the
lowest number of reads mapping to the large and small rRNA subunit from a sample
was 18,597, the METAXA2 result read depth was rarefied to 18,597 reads for all samples
prior to estimating alpha diversity using both the Shannon index and the Chao1
richness index. In early life, high-Bifidobacterium samples had significantly lower alpha
diversity by both the Shannon index (Kruskal-Wallis test, P 0.0001) and the Chao1
richness index (Kruskal-Wallis test, P 0.0002). In the later-life samples, there was no
significant difference in alpha diversity between infants who were high or low Bifido-
bacterium in early life by either the Shannon index (Kruskal-Wallis test, P 0.16) or the
Chao1 richness index (Kruskal-Wallis test, P 0.30). However, the later-life samples did
have a significantly greater alpha diversity by both the Shannon index (Wilcoxon paired
test, P 0.003) and the Chao1 richness index (Wilcoxon paired test, P 0.0001) (see
Fig. S1 in the supplemental material). There were significant differences in delivery
mode between high- and low-Bifidobacterium infants (chi-square test, P 0.00956),
with 15 of the 18 high-Bifidobacterium infants delivered by Caesarean section compared
to 4 of 13 low-Bifidobacterium infants delivered by Caesarean section.
Metagenomic sequencing results. The Bangladeshi samples were sequenced in
three separate lanes in three separate runs. Runs 1 and 2 contained a mixture of high-
and low-Bifidobacterium samples from early life. Run 3 contained all year 2 samples.
There were no significant differences in merged read depth by run (analysis of variance
[ANOVA], P 0.92) (Table S1). There were no significant differences in the number of
contigs generated from samples in run 1 and run 2 (Kruskal-Wallis test, P 0.87);
however, there were significantly more contigs generated for low-Bifidobacterium
early-life samples than for high-Bifidobacterium early-life samples. Run 3 did have
significantly more contigs than runs 1 and 2 (Kruskal-Wallis test comparing runs 1 and
3 and comparing runs 2 and 3, both P 0.0001), likely related to the increased diversity
of the microbiome between the early-life and later-life samples. Table S1 presents the
read depth, number of contigs produced, the total contig length, and the N50 for each
sample. After merging paired-end reads, sequencing depth was significantly greater
in high-Bifidobacterium early-life samples than in low-Bifidobacterium early-life samples
(t test, P 0.002, mean 16,156,413 reads in high-Bifidobacterium samples and mean
13,672,554 reads in low-Bifidobacterium samples) (Fig. S2). However, the number of
contigs and the total assembly length were significantly lower in high-Bifidobacterium
early-life samples than in low-Bifidobacterium early-life samples (Kruskal-Wallis test;
contig count, P 0.0001; total length, P 0.0001). This is consistent with the alpha
diversity analysis which found lower diversity in the high-Bifidobacterium samples, as a
less diverse microbiome will have fewer different genomes present and will therefore
have a shorter total assembly length. If bias exists, the lower number of reads in the
low-Bifidobacterium samples will tend to bias results toward finding an increased
number of ARGs in high-Bifidobacterium samples. Comparison to the ResFinder data-
base with default settings revealed that high-Bifidobacterium samples in early life
had significantly fewer classes of ARGs present than low-Bifidobacterium samples
TABLE 1 Characteristics of Bangladeshi infants with high- and low-Bifidobacterium samples in early lifea
Bifidobacterium level
in early life
No. of samples
from: No. of male infants
No. of C-section
deliveries
Early-life sample wk
of collection,
wk 6/wk 11/wk 15
Mean wk of
early-life
sample
collectionEarly life Yr 2 Early life Yr 2 Early life Yr 2
High 18 7 12 3 15 5 8/7/3 9.4
Low 13 8 8 4 4 1 8/4/1 8.2
P value P 1 P 1 P 0.0096 P 0.072 P 0.59
aP values were calculated using a chi-square test; a P value of 0.05 was used for significance.
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(P 0.0021) (Fig. 2A). High-Bifidobacterium samples had a median of 4 ARG classes
present per sample (range of 2 to 8 ARG classes per sample) compared to low-
Bifidobacterium samples, which had a median of 7 ARG classes present per sample
(range of 3 to 11 ARG classes per sample).
Looking across all early-life samples using ResFinder, there are a total of 11 classes
of ARGs present: aminoglycoside; beta-lactam; fluoroquinolone; fosfomycin; macrolide,
lincosamide, and streptogramin B (MLS); phenicol; sulfonamide; tetracycline; tri-
methoprim; glycopeptide; and nitroimidazole. All 11 of these classes were present in
the low-Bifidobacterium samples, but only 9 of the classes were present in high-
Bifidobacterium samples. The classes present in the low-Bifidobacterium early-life sam-
FIG 2 (A) Number of AMR classes with at least one ARG detected by ResFinder in high- and low-Bifidobacterium samples in early life. There are significantly
fewer AMR classes present in high-Bifidobacterium samples (P 0.0021). (B) Number of different ARGs detected by ResFinder in early life. There are significantly
fewer ARGs present in high-Bifidobacterium samples (P 0.0001). (C) Number of different AMR classes at year 2; there is no significant difference by
Bifidobacterium levels in early life (P 0.725). (D) Number of different ARGs detected by ResFinder at year 2. There is no significant difference by Bifidobacterium
levels in early life (P 0.685). All statistical testing was performed using a Kruskal-Wallis test. P value for significance is 0.025.
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ples but absent in high-Bifidobacterium early-life samples were glycopeptide resistance
(present in 2 low-Bifidobacterium samples) and nitroimidazole (present in 1 low-
Bifidobacterium sample). All other classes were detected in at least 9 of the 31 samples.
Only a single class, MLS, was present in all samples (Table S2).
High-Bifidobacterium samples in early life also had significantly fewer transferable
ARGs present (P 0.0001) (Fig. 2B). This difference became greater after dividing the
number of ARGs present per sample by the number of merged reads included in the
assembly per sample, supporting the idea that the difference is not due to differences
in sequencing depth (P 0.0001) (Fig. S3). High-Bifidobacterium samples had a median
of 7.5 ARGs per sample (range, 2 to 19), and low-Bifidobacterium samples had a median
of 20 ARGs per sample (range, 6 to 37). There were a total of 108 ARGs detected by
ResFinder in early-life samples. Of these, 103 were present in low-Bifidobacterium
samples and 50 were present in high-Bifidobacterium samples (Table 2). Of the 50 ARGs
present only in the high-Bifidobacterium samples, five were present in only a single
high-Bifidobacterium sample. These ARGs were str (aminoglycoside resistance), aadA1
(aminoglycoside resistance), cat(pc221) (phenicol resistance), blaLEN12 (beta-lactam re-
sistance), and strA (aminoglycoside resistance). These genes were found in 4 separate
samples, with aadA1 and strA detected in the same sample. The five genes found only
in high-Bifidobacterium samples stand in contrast to 58 ARGs found only in low-
Bifidobacterium samples. Of these 58 genes, 41 were found in only a single low-
Bifidobacterium sample, and 11 were found in two low-Bifidobacterium samples. Due to
our small cohort size, an ARG present in only one low-Bifidobacterium sample would
have a prevalence of 8% in low-Bifidobacterium infants and 3% in all infants. There was
a median of 2 unique ARGs per low-Bifidobacterium sample (range, 0 to 7 ARGs per
sample). Two genes were found in three low-Bifidobacterium samples: one was a
beta-lactam resistance gene, blaSHV-1, and the other was a tetracycline resistance gene,
tet(31). Two genes were found only in 4 of the 15 low-Bifidobacterium samples: one was
a beta-lactam resistance gene, blaACI-1, and one was a tetracycline resistance gene,
tet(Q). Two genes were found only in 5 of the 15 low-Bifidobacterium samples, an MLS
resistance gene, erm(T), and a fluoroquinolone resistance gene, oqxB. There was not a
significant difference between ARG count and delivery mode in early life in either the
high-Bifidobacterium infants (Kruskal-Wallis test, P 0.40) or the low-Bifidobacterium
infants (Kruskal-Wallis test, P 0.76).
NCBI BLAST (33), in combination with a custom python script (https://github.com/
akre96/ResistBlast), was used to attempt to predict the taxa of origin of contigs
identified as containing an ARG by ResFinder. The family Enterobacteriaceae was the
most common predicted origin of ARGs in both high- and low-Bifidobacterium samples,
accounting for an average of 49% of the ARGs per sample detected in the high-
Bifidobacterium samples and 43% of the ARGs per sample detected in the low-
Bifidobacterium samples. In the high-Bifidobacterium samples, other detected families of
origin in decreasing average percentage of ARGs per sample were as follows: Entero-
coccaceae (34% of ARGs on average), Staphylococcaceae (30% of ARGs on average),
Streptococcaceae (29% of ARGs on average), Bifidobacteriaceae (19% of ARGs on aver-
age), mixed (meaning that the top three hits from BLAST results belonged to multiple
families; 19% of ARGs on average), unknown (meaning either no hits by BLAST or
TABLE 2 Number of ARGs present in Bangladeshi samples by ResFinder
Bifidobacterium
level Time
No. of ARGs
Total
present
Unique to
Bifidobacterium
level
Detected
in only a
single sample
Median per
sample (range)
High Early life 50 5 5 7.5 (2–19)
Low Early life 103 58 41 20 (6–37)
High Yr 2 73 27 23 24 (11–48)
Low Yr 2 62 16 12 21.5 (14–28)
Early-Life Bifidobacteria and Antimicrobial Resistance
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that all hits corresponded to uncultured bacteria; 17% of ARGs on average), and
Actinomycetaceae (7.7% of ARGs on average). All families detected in the high-
Bifidobacterium samples were also detected in the low-Bifidobacterium samples, but
the low-Bifidobacterium samples identified ARGs originating in additional taxa. In
the low-Bifidobacterium samples, detected families of origin, in decreasing average
percentage of ARGs per sample, were as follows: mixed (20% of ARGs on average),
Campylobacteraceae (19% of ARGs on average), Staphylococcaceae (12% of ARGs on
average), Enterococcaceae (11% of ARGs on average), unknown (11% of ARGs on
average), Moraxellaceae (10% of ARGs on average), Streptococcaceae (10% of ARGs
on average), Bifidobacteriaceae (6.0% of ARGs on average), Peptostreptococcaceae
(5.9% of ARGs on average), Bacteroidaceae (5.8% of ARGs on average), Flavobacte-
riaceae (5.0% of ARGs on average), Prevotellaceae (2.8% of ARGs on average), and
Actinomycetaceae (2.7% of ARGs on average).
There were no significant differences in merged read depth of the later-life (year 2)
samples between infants who were high Bifidobacterium in early life and those who
were low Bifidobacterium in early life (t test, P 0.90). By year 2, all infants included had
65% relative abundance of Bifidobacterium (Fig. 1D), an expected result as Bifidobac-
terium levels are known to decrease with the introduction of complementary foods and
to fall further when children are completely weaned (15). The relatively high Bifidobac-
terium levels (50%) in some infants may reflect the fact that by 2 years of age, 80%
of Bangladeshi women are still providing some breast milk to their child (34). At year
2, ResFinder detected no significant difference in the number of AMR classes or the
number of ARGs detected in samples from infants who had high levels of Bifidobacte-
rium in early life compared to infants who had low levels of Bifidobacterium in early life
(Kruskal-Wallis test, P 0.725 for AMR class and P 0.685 for ARGs) (Fig. 2C and D). The
same 11 classes of transferable ARGs present in low-Bifidobacterium samples in early life
were detected at year 2 in both high- and low-Bifidobacterium samples: aminoglyco-
side, beta-lactam, fluoroquinolone, fosfomycin, glycopeptide, MLS, nitroimidazole,
phenicol, sulfonamide, tetracycline, and trimethoprim. At year 2, 89 ARGs were de-
tected in at least one sample. There were 73 different ARGs detected in samples from
infants with high Bifidobacterium in early life but only 62 different ARGs detected in
samples from infants with low Bifidobacterium (Table 2). Of the 27 ARGs found only in
samples from infants who had high Bifidobacterium in early life, 23 were found in only
one sample, 3 were found in two samples, and one gene (cfxA4, beta-lactam resistance)
was present in 3 samples. Of the 16 ARGs found only in samples from infants who had
low Bifidobacterium in early life, 12 were found in only one sample and 4 were found
in two samples.
At year 2, Enterobacteriaceae remained the most common predicted origin of ARGs
for infants who had high levels of Bifidobacterium in early life, accounting for an average
of 38% of ARGs per sample detected in the year 2 samples. For infants who were low
Bifidobacterium in early life, a mixed origin (meaning that the top hits from BLAST were
from more than one family) was the most common predicted origin of ARGS, account-
ing for an average of 36% of ARGs per sample at year 2. In the year 2 samples from
infants who were initially high Bifidobacterium, the detected families of origin in
decreasing order of average per-sample origin were as follows: mixed, unknown
(meaning either no BLAST hits or that the top three hits were all uncultured), Strepto-
coccaceae, Enterococcaceae, Pasteurellaceae, Prevotellaceae, Lactobacillaceae, Bifidobac-
teriaceae, Bacteroidaceae, Brachyspiraceae, and Campylobacteraceae. In the year 2 sam-
ples from infants who were low Bifidobacterium in early life, the detected families of
origin in decreasing order of average per-sample origin were as follows: Enterobacte-
riaceae, unknown, Enterococcaceae, Streptococcaceae, Peptostreptococcaceae, Prevotel-
laceae, Bacteroidaceae, Bifidobacteriaceae, Pasteurellaceae, Clostridiaceae, and Pseu-
domonadaceae.
The merged reads were then classified as ARGs using the AMR pipeline and
normalized by the number of reads mapping to 16S rRNA genes to examine both
transferable and nontransferable ARGs. Table S1 reports on the number of 16S reads
Taft et al.
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identified by METAXA2 and the number of reads mapping to ARGs by AMR.
Normalization was completed to calculate what is referred to as abundance using the
number of reads mapping to each ARG, the length of the full gene of each ARG, and
the number of reads mapping to 16S rRNA genes, as described by Li et al. (35)
Comparing the total numbers of normalized reads mapping to ARGs by AMR
between high- and low-Bifidobacterium samples, high-Bifidobacterium samples had a
significantly lower abundance of ARGs than low-Bifidobacterium samples (median for
high Bifidobacterium, 0.69; median for low Bifidobacterium, 1.42; P 0.037) (Fig. 3A).
There was no significant difference in total ARGs by delivery mode in either the
high-Bifidobacterium infants (P 0.31) or the low-Bifidobacterium infants (P 0.88).
Because the MEGARes database organizes ARGs into the acyclical categories of
group, mechanism, and class (36), high- and low-Bifidobacterium samples were com-
pared for differences at each of these levels as well as for differences in individual
ARGs. There were a total of 18 distinct AMR classes detected in the early-life samples
using AMR, leading to a Bonferroni-corrected P value of 0.00278 to detect a
significant difference in normalized ARG abundance in class between high- and
low-Bifidobacterium samples using a Kruskal-Wallis test. Of these 18 classes, 10 were at
higher normalized abundance levels in low-Bifidobacterium early-life samples: amino-
coumarins (P 0.000141), aminoglycosides (P 0.000987), bacitracin (P 0.000242),
beta-lactams (P 0.0000127), cationic antimicrobial peptides (P 0.00186), elfamycins
(P 0.00000582), fluoroquinolones (P 0.0000588), multidrug resistance (MDR)
(P 0.000122), rifampin (P 0.0000151), and sulfonamides (P 0.000181). In addition,
the high-Bifidobacterium samples were significantly higher in a single class of AMR in
early-life samples, MLS (P 0.00000503). Because beta-lactam antibiotics are clinically
important, to further explore the resistance to beta-lactam present in these samples,
the 240 ARGs belonging to the class of beta-lactamases were classified as either
transferable (229 ARGs) or nontransferable (11 ARGs) based on whether or not the gene
was included in the ResFinder database, and the abundances of both transferable
and nontransferable beta-lactamases were compared between high- and low-
Bifidobacterium samples using a Kruskal-Wallis test. Both transferable and nontransfer-
able beta-lactam ARGs were significantly increased in low-Bifidobacterium infants. For
FIG 3 Total ARG reads normalized by read length and 16S gene read count in early life in Bangladesh. (A) Infants with high levels of Bifidobacterium had
significantly lower levels of ARGs in their metagenomes (P 0.037 by Kruskal-Wallis test) in early life. (B) At year 2, there was no significant difference in ARGs
between infants who had high and low levels of Bifidobacterium in early life (P 0.247 by Kruskal-Wallis). P value for significance is 0.05, as total ARG is the
sum of all other ARGs that are compared later to identify particular differences.
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transferable beta-lactam ARGs, the median normalized abundance was 0.0941 in the
low-Bifidobacterium early-life samples but only 0.00171 in the high-Bifidobacterium
samples (P 0.0001). For nontransferable beta-lactam ARGs, the median normalized
abundance was 0.0505 for the low-Bifidobacterium samples but only 0.00286 for the
high-Bifidobacterium early-life samples (P 0.0001).
At the mechanism level, a total of 48 mechanisms were detected, resulting in a
Bonferroni-corrected P value of 0.00104. A total of 13 of these mechanisms were
significantly elevated in the low-Bifidobacterium early-life samples: aminocoumarin-
resistant DNA topoisomerases (P 0.000141), aminoglycoside efflux pumps (P
0.000362), aminoglycoside efflux regulator (P 0.000348), class A beta-lactamases
(P 0.0000229), EF-Tu inhibition (P 0.00000582), fluoroquinolone-resistant DNA to-
poisomerases (P 0.0000496), multidrug-resistant (MDR) mutant porin proteins
(P 0.0000320), MDR regulator (P 0.0000874), multidrug efflux pumps (P
0.000181), penicillin binding protein (P 0.0000735), rifampin-resistant beta-subunit of
RNA polymerase RpoB (P 0.0000151), sulfonamide-resistant dihydropteroate syn-
thases (P 0.000181), and undecaprenyl pyrophosphate phosphatase (P 0.000242).
In high-Bifidobacterium early-life samples, only a single mechanism was significantly
increased, 23S rRNA methyltransferases (P 0.00000281); this mechanism belongs to
class MLS. There were 178 different AMR groups (details on groups available on the
MEGARes website, https://megares.meglab.org/browse/) detected in the early-life sam-
ples, resulting in a Bonferroni-corrected P value of 0.000281 for significance. Of these,
25 groups were significantly higher in the low-Bifidobacterium early-life samples: ACRB
(P 0.0000464), ACRD (P 0.000248), AMPH (P 0.0000796), ASMA (P 0.000106),
BACA (P 0.000242), BAER (P 0.000211), CPXA (P 0.0000465), CPXAR (P
0.000110), CRP (P 0.0000417), EMRB (P 0.000110), ERMD (P 0.000276), EMRK
(P 0.000170), EMRR (P 0.000242), EVGA (P 0.000182), FOLP (P 0.000265), GYRA
(P 0.000164), GYRB (P 0.0000602), HNS (P 0.0000100), MARR (P 0.000215),
MDTB (P 0.000248), OMPF (P 0.0000320), PARC (P 0.000226), PARE (P
0.000101), RPOB (P 0.0000151), and TUFAB (P  0.00000582). There was also a single
group of AMR elevated in the high-Bifidobacterium samples, ERMX (P 0.00000279),
belonging to mechanism 23S rRNA methyltransferases (Table 3 summarizes class,
mechanism, and group results). There were a total of 724 different ARGs detected in the
early-life samples, resulting in a Bonferroni correction for multiple comparisons of
0.0000691. As a result of this stringent correction, there were 6 genes significantly
enriched in low-Bifidobacterium samples and 4 genes significantly enriched in high-
Bifidobacterium samples (Table S3). All four genes enriched in the high-Bifidobacterium
samples belonged to the group ERMX, and BLAST searching against the full reference
sequence of the gene indicated that all four ERMX genes are known to occur in
Bifidobacterium. All classes, mechanisms, groups, and genes that were significantly
different between the high- and low-Bifidobacterium samples in the AMR anal-
ysis were present in at least 2 high-Bifidobacterium samples and at least 2 low-
Bifidobacterium samples.
To confirm that the AMR results were not an artifact of the method, early-life
samples were also analyzed using ShortBRED with the Comprehensive Antibiotic
Resistance Database (CARD) 2017 pregenerated ShortBRED database (37, 38). Because
CARD does not have the acyclical classification scheme of MEGARes, only total counts
and individual gene counts were compared between high- and low-Bifidobacterium
samples. In addition, the number of ARGs included in CARD is smaller than the number
of ARGs included in MEGARes, which will reduce the number of ARGs detected in the
early-life samples. Results were generally similar to AMR results with a significantly
lower total AMR value in high-Bifidobacterium samples than in low-Bifidobacterium
samples (Kruskal-Wallis test, P 0.0014) (Fig. S4). ShortBRED identified a total of 237
ARGs in the early-life samples, resulting in a Bonferroni-corrected P value of 0.000211
for significance. There were a total of 14 genes that were significantly reduced in the
high-Bifidobacterium samples using a Kruskal-Wallis test, including ARO3002985 (cat-
ionic antimicrobial peptide resistance, P 0.000147), ARO3003369 (elfamycin resis-
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tance, P 0.0000454), ARO3004042 (MDR, P 0.000143), ARO3000518 (MDR, P 
0.0000153), ARO3003890 (fosfomycin, P  0.0000735), ARO3000832 (MDR, P  0.0000531),
ARO3003288 (rifampin, P  0.00000991), ARO3003807 (MDR, P  0.000180), ARO3003950
(nitroimidazole, P  0.000110), ARO3002818 (MLS, P  0.000161), ARO3003511 (MDR,
TABLE 3Median normalized abundance for AMRs identified by MEGARes that were significantly different between the high- and low-
Bifidobacterium samples in Bangladesha
Database level and AMR class, mechanism, or group value
Median normalized abundance in samples
(range) with:
Kruskal-Wallis
test P valueHigh Bifidobacterium Low Bifidobacterium
Class
Aminocoumarins 0.000275 (0–0.00603) 0.0236 (0–0.0708) 0.000141
Aminoglycosides 0.00374 (0–0.147) 0.0768 (0.00526–0.785) 0.000987
Bacitracin 0 (0–0.0166) 0.0116 (0.000491–0.129) 0.000242
Beta-lactams 0.00437 (0–0.068) 0.221 (0.0162–1.33) 0.0000127
Cationic antimicrobial peptides 0 (0–0.0594) 0.0322 (0–0.736) 0.00186
Elfamycins 0.00325 (0–0.0181) 0.0870 (0.00977–0.231) 0.00000582
Fluoroquinolones 0.00136 (0–0.0430) 0.100 (0.00238–0.448) 0.0000588
Multidrug resistance (MDR) 0.00672 (0–0.319) 0.567 (0.0204–4.19) 0.000122
Rifampin 0.00241 (0–0.0114) 0.0920 (0.00233–0.134) 0.0000150
Sulfonamides 0.000658 (0–0.00883) 0.0273 (0.000373–0.290) 0.000181
Macrolides, lincosamides, and streptogramins (MLS) 0.367 (0.224–2.74) 0.0760 (0.000908–0.273) 0.00000503
Mechanism
Aminocoumarin-resistant DNA topoisomerases (class aminocoumarins) 0.000275 (0–0.00603) 0.0236 (0–0.0708) 0.000141
Aminoglycoside efflux pumps (class aminoglycosides) 0.000124 (0–0.0266) 0.0251 (0.00184–0.371) 0.000362
Aminoglycoside efflux regulator (class aminoglycosides) 0 (0–0.0166) 0.00577 (0–0.147) 0.000348
Class A beta-lactamases (class beta-lactamases) 0 (0–0.0455) 0.0591 (0.00160–0.725) 0.0000229
EF-Tu inhibition (class elfamycins) 0.00325 (0–0.018) 0.0870 (0.00977–0.231) 0.00000582
Fluoroquinolone-resistant DNA topoisomerases (class fluoroquinolones) 0.00136 (0–0.0430) 0.0729 (0.00238–0.447) 0.0000496
MDR mutant porin proteins (class MDR) 0.000356 (0–0.00686) 0.0227 (0.000493–0.105) 0.0000320
MDR regulator (class MDR) 0.00400 (0–0.137) 0.244 (0.0109–1.54) 0.0000874
Multidrug efflux pumps (class MDR) 0.00237 (0–0.194) 0.293 (0.00892–2.56) 0.000181
Penicillin binding protein (class beta-lactams) 0.00354 (0–0.0184) 0.0819 (0.00699–0.345) 0.0000735
Rifampin-resistant beta-subunit of RNA polymerase RpoB (class rifampin) 0.00241 (0–0.0114) 0.0920 (0.00233–0.134) 0.0000150
Sulfonamide-resistant dihydropteroate synthases (class sulfonamides) 0.000658 (0–0.00883) 0.0273 (0.000373–0.290) 0.000181
Undecaprenyl pyrophosphate phosphatase (class bacitracin) 0 (0–0.0166) 0.0116 (0.000491–0.129) 0.000242
23S rRNA methyltransferases (class MLS) 0.366 (0.220–2.72) 0.0140 (0–0.203) 0.00000281
Group
ACRB (class MDR) 0 (0–0.00455) 0.0141 (0–0.0836) 0.0000464
ACRD (class aminoglycoside) 0 (0–0.0117) 0.0110 (0.000619–0.114) 0.000248
AMPH (class beta-lactam) 0.000454 (0–0.00872) 0.0176 (0.00131–0.123) 0.0000796
ASMA (class MDR) 0.000312 (0–0.00944) 0.0163 (0.000575–0.108) 0.000106
BACA (class bacitracin) 0 (0–0.0166) 0.0116 (0.000491–0.129) 0.000242
BAER (class MDR) 0 (0–0.00932) 0.0111 (0.000280–0.123) 0.000211
CPXA (class MDR) 0 (0–0.00772) 0.00856 (0–0.0814) 0.0000465
CPXAR (class MDR) 0 (0–0.0178) 0.0265 (0.000554–0.231) 0.000110
CRP (class MDR) 0.000726 (0–0.0105) 0.0236 (0.00144–0.132) 0.0000417
EMRB (class MDR) 0 (0–0.0124) 0.0158 (0.000659–0.131) 0.000110
EMRD (class MDR) 0 (0–0.00411) 0.00416 (0–0.0436) 0.000276
EMRK (class MDR) 0 (0–0.00802) 0.00534 (0–0.107) 0.000170
EMRR (class MDR) 0 (0–0.0129) 0.00909 (0.00114–0.104) 0.000242
EVGA (class MDR) 0 (0–0.0101) 0.00597 (0–0.113) 0.000182
FOLP (class sulfonamides) 0.000517 (0–0.00800) 0.0273 (0–0.149) 0.000265
GYRA (class fluoroquinolones) 0.000342 (0–0.00969) 0.0256 (0.000463–0.110) 0.000164
GYRB (class fluoroquinolones) 0.000230 (0–0.0145) 0.0225 (0.00132–0.144) 0.0000602
HNS (class MDR) 0.000179 (0–0.00849) 0.0152 (0.00147–0.0966) 0.0000100
MARR (class MDR) 0 (0–0.00611) 0.00428 (0–0.0902) 0.000215
MDTB (class MDR) 0 (0–0.0120) 0.0142 (0.000601–0.109) 0.000248
OMPF (class MDR) 0.000356 (0–0.00686) 0.0163 (0.000493–0.0930) 0.0000320
PARC (class fluoroquinolones) 0.000544 (0–0.0134) 0.0197 (0–0.132) 0.000226
PARE (class aminocoumarins) 0.000275 (0–0.00603) 0.0228 (0–0.0708) 0.000101
RPOB (class rifampin) 0.00241 (0–0.0114) 0.0920 (0.00233–0.134) 0.0000150
TUFAB (class elfamycin) 0.00325 (0–0.0181) 0.0870 (0.00977–0.230) 0.00000582
ERMX (class MLS) 0.366 (0.220–2.72) 0.0109 (0–0.0450) 0.00000279
aP value for significant difference at the class level was 0.00278, at the mechanism level was 0.00104, and at the group level was 0.000281.
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P  0.000173), ARO3000826 (MDR, P  0.0000159), ARO3003317 (fluoroquinolone, P 
0.000130), and ARO3000263 (MDR, P  0.000111). There was a single gene that was
significantly enriched in the high-Bifidobacterium samples using a Kruskal-Wallis test,
ARO3000596 (MLS, P  0.00000282). More genes were identified as significantly
different by ShortBRED than by AMR, likely resulting from the smaller size of CARD,
meaning that a less stringent Bonferroni correction was applied to the ShortBRED
analysis. Both ShortBRED and AMR identified increased ErmX resistance in the
high-Bifidobacterium samples. Unlike AMR, ShortBRED did not identify any beta-
lactamases that were significantly enriched in the low-Bifidobacterium samples; how-
ever, the specific gene identified as enriched by AMR was not included in CARD.
ShortBRED identified significant differences in a gene providing resistance to fosfomy-
cin and a gene providing resistance to nitroimidazole, where AMR did not identify
any differences in resistance to either of these resistance classes; this may relate to the
more stringent P value correction used in the AMR analysis.
In the year 2 samples, there was no significant difference in the number of AMR
classes or ARGs detected by ResFinder (P  0.725 and P  0.685, respectively;
Kruskal-Wallis test). For the AMR pipeline at year 2, only ARGs, groups, mechanisms,
and classes that were significantly different in early life were compared. There were no
significant differences at year 2 in total normalized ARGs between infants who had high
Bifidobacterium and infants who had low Bifidobacterium in early life (P  0.247,
Kruskal-Wallis test). Only the ARGs, groups, mechanisms, and classes that were signif-
icantly different in early life were tested in later life to minimize multiple-comparison
issues. Despite this, there were no remaining significant differences in any specific ARG,
group, mechanism, or class at year 2.
Comparing early-life samples with year 2 samples, there was no significant differ-
ence in the number of AMR classes or ARGs detected by ResFinder in the low-
Bifidobacterium samples (P  0.672 and P  0.324, respectively; Wilcoxon paired test).
However, there was a significant increase in the number of both AMR classes and ARGs
in the high-Bifidobacterium samples (P  0.022 and P  0.022, respectively; Wilcoxon
paired test). The AMR pipeline had contrasting results: there was no significant
difference in AMR abundance between early-life and year 2 samples for high-
Bifidobacterium infants (Wilcoxon paired test, P  0.938). In contrast, there was a
significant drop in AMR abundance between early-life and year 2 infants with low levels
of Bifidobacterium in early life (Wilcoxon paired test, P  0.0156) (Fig. 4).
To further confirm that levels of Bifidobacterium were different between the high-
and low-Bifidobacterium samples, quantitative PCR (qPCR) was conducted to measure
total bacteria, total Bifidobacterium, and total Enterobacteriaceae in all samples where
sufficient DNA remained after sequencing. The Enterobacteriaceae family was chosen
for qPCR because it was the most common predicted origin of AMR in the ResFinder
analysis. This analysis included 28 of the 31 early-life samples and 14 of the 15 year 2
samples. In early life, the high-Bifidobacterium samples had significantly lower total
bacteria than the low-Bifidobacterium samples (Kruskal-Wallis test, P  0.00402)
(Fig. S5A), but in later life there was no significant difference in total bacteria between
these groups (Kruskal-Wallis test, P  0.338) (Fig. S5A). The infants with early-life high
Bifidobacterium exhibited a significant increase in total bacteria between the early-life
and year 2 samples (Wilcoxon paired test, P  0.0156), but there was no significant
difference in total bacteria between early life and year 2 in the early-life low-
Bifidobacterium infants (Wilcoxon paired test, P  0.312). However, the total Bifidobac-
terium qPCR confirmed that in early life the high-Bifidobacterium samples had signifi-
cantly more Bifidobacterium than the low-Bifidobacterium samples (Kruskal-Wallis test,
P 0.0001) (Fig. S5B). There was no significant difference in Bifidobacterium levels
between the two groups at year 2 (Kruskal-Wallis test, P  0.565). While not reaching
significance, there was a trend toward a reduction in Bifidobacterium levels in the
high-Bifidobacterium group when comparing early-life and year 2 samples (Wilcoxon
paired test, P  0.0781). There was also a trend toward increased Bifidobacterium levels
in infants in the low-Bifidobacterium group between early life and year 2 (Wilcoxon
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paired test, P  0.0625). The Enterobacteriaceae qPCR found that high-Bifidobacterium
infants in early life had significantly lower Enterobacteriaceae than low-Bifidobacterium
infants (Kruskal-Wallis test, P  0.00961) (Fig. S5C). By year 2, the difference in
Enterobacteriaceae between the high- and low-Bifidobacterium groups was only bor-
derline significant (Kruskal-Wallis test, P  0.0693). There was no significant difference
in Enterobacteriaceae between the early-life and year 2 samples in the infants with low
Bifidobacterium in early life (Wilcoxon paired test, P 0.812), but there was a significant
increase in Enterobacteriaceae in the high-Bifidobacterium infants between early life and
year 2 (Wilcoxon paired test, P  0.0156). The lower total bacteria and Enterobacteri-
aceae in the samples with higher levels of Bifidobacterium are consistent with our
hypothesis that acid production by Bifidobacterium suppresses the growth of other
taxa, potentially allowing niches that might otherwise be filled by AMR-carrying bac-
teria to remain open during infancy. The qPCR results for total Bifidobacterium levels
were significantly correlated with the Bifidobacterium relative abundance calculated
from the 16S rRNA gene sequencing data (Spearman’s rho 0.82, P 0.0001) and with
the Bifidobacterium relative abundance calculated from the WGS data (Spearman’s
rho  0.73, P 0.0001). The correlation becomes stronger after dividing the Bifidobac-
terium qPCR results by the total bacterial qPCR results (with 16S rRNA gene sequencing
data, rho  0.86, P 0.0001, and with WGS data, rho  0.78, P 0.0001). The value of
the relative abundance calculated from the qPCR data is potentially problematic, as 10
of the 18 high-Bifidobacterium samples were predicted to have a Bifidobacterium
relative abundance greater than 100% and 3 samples were predicted to have a
Bifidobacterium relative abundance greater than 200%. This may be related to the use
of different 16S regions for the two sets of primers. In addition, higher total Bifidobac-
terium levels in early life correlated with reduced total normalized AMR abundance
(from AMR results, Spearman’s test, rho  0.500, P  0.00736), but there was no
significant correlation between either Enterobacteriaceae and total normalized AMR
abundance (Spearman’s test, P  0.134) or total bacteria and total normalized AMR
abundance (Spearman’s test, P  0.601).
FIG 4 Comparison between early-life and year 2 AMR levels. (A) There was a significant increase in the number of transferable ARGs present (as detected by
ResFinder) in the high-Bifidobacterium infants between early life and year 2 (P 0.0223, Wilcoxon paired test). There was no significant difference in the number
of transferable ARGs present in low-Bifidobacterium infants between the early-life and year 2 samples (P  0.324, Wilcoxon paired test). (B) There was no
significant difference in AMR abundance between early life and year 2 in infants who had high levels of Bifidobacterium in early life (P  0.938, Wilcoxon paired
test). There was a significant decrease in AMR abundance between early life and year 2 in infants who had low levels of Bifidobacterium in early life (P  0.0156,
Wilcoxon paired test). P value for significance is 0.05.
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Additional cohort analysis: infants from Sweden. To confirm the findings of AMR
reduction detected in the Bangladeshi cohort, the month 4 and month 12 samples from
the study by Bäckhed et al. (30) of infant microbial colonization dynamics of Swedish
infants were analyzed using the AMR pipeline. The ResFinder analysis was not
completed in the Swedish cohort because at month 4 higher levels of Bifidobacterium
correlate with a lower trimmed read depth (Spearman’s test, P 0.0001), which will
bias the results away from the null hypothesis. There was no significant correlation
between Bifidobacterium and read depth at month 12 (Spearman’s test, P 0.206). The
AMR pipeline analysis does include a normalization step that adjusts for read depth.
Table S4 presents the read depth of downloaded sequence files, host-subtracted
sequence files, trimmed reads, number of 16S reads by METAXA2, and number of reads
mapping to ARGs by AMR. To first explore the connection between Bifidobacterium
levels and total AMR including all infants at month 4, total AMR was log transformed.
A regression model was then run with the log-transformed total AMR as the outcome
variable and the Bifidobacterium level in the sample, the number of times that an infant
received antibiotics before age 4 months, and delivery mode as predictor variables
using the glm command in R 3.4.3. Relative abundance of Bifidobacterium in the sample
was significantly associated with the log-transformed total AMR (P 0.00785,
1.5654), while the number of times that an infant received antibiotics (P 0.657)
and delivery mode (P 0.24) were nonsignificant. The association between Bifidobac-
terium and the log of the total AMR remained significant after removing antibiotic
exposure and delivery mode from the model (P 0.0159, 1.3886). This is con-
sistent with increasing levels of Bifidobacterium correlating with decreasing levels of
AMR. However, as only 5 infants of the 100 Swedish infants ever received antibiotics,
power may be limited to detect the actual influence of antibiotic exposure on AMR
level.
Of the 100 infants at month 4, only 6 met the criteria for high Bifidobacterium while
48 met the criteria for low Bifidobacterium (Fig. 5). At month 4, there was no significant
difference in the total abundances of ARGs detected in high- and low-Bifidobacterium
samples (median for high Bifidobacterium, 1.35; for low Bifidobacterium, 3.27;
P 0.0613) (Fig. 6). In this cohort, there were 17 different AMR classes detected,
resulting in a Bonferroni-corrected P value of 0.00294 for a significant difference in class
abundance at month 4. Only one of the seventeen classes differed significantly be-
tween high- and low-Bifidobacterium infants, tetracyclines (Kruskal-Wallis test,
P 0.000294), with low-Bifidobacterium infants having significantly higher levels of
tetracycline resistance.
There were a total of 47 AMR mechanisms detected in the month 4 samples
classified as high or low Bifidobacterium, resulting in a Bonferroni-corrected P value of
0.00106 for comparisons. Only two mechanisms were significantly enriched in month 4
low-Bifidobacterium samples: class A beta-lactamases (P 0.000347) and tetracycline
resistance ribosomal protection proteins (P 0.000153). No AMR mechanisms were
significantly enriched in high-Bifidobacterium samples. There were 173 different AMR
groups present in the month 4 high- or low-Bifidobacterium samples, resulting in a
Bonferroni-corrected P value of 0.000289 for significance. There was one group signif-
icantly increased in the low-Bifidobacterium samples, TETQ (P 0.0000467). There were
599 different ARGs detected in the month 4 high- and low-Bifidobacterium samples,
resulting in a Bonferroni-corrected P value of 0.0000835. No individual ARGs differed
significantly between the high- and low-Bifidobacterium month 4 samples.
By month 12, the relative abundance of Bifidobacterium for all infants had fallen
below 30%, and below 20% for all infants except one (Fig. 5C). The one infant with
Bifidobacterium abundance above 20% at month 12 was an infant with Bifidobacterium
abundance below 20% at month 4, which suggests that infants in the Swedish cohort
may have had variable levels of Bifidobacterium, as was observed in the Bangladeshi
cohorts. The Swedish infants had much lower rates of breastfeeding at 1 year than the
breastfeeding rates typical of Bangladesh. Only 14 of 98 infants with information on
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feeding at month 12 received any breast milk in their diet, which may explain why
children in Sweden tended to have a lower prevalence of Bifidobacterium at month 12
than children in Bangladesh at year 2. At month 12, infants who had low levels of
Bifidobacterium at month 4 had significantly higher total ARG abundance than infants
with high levels of Bifidobacterium at month 4 (P 0.0105) (Fig. 7). Because the only
significant difference in AMR classes between high and low Bifidobacterium was in
tetracycline, only this class was tested at month 12, using a P value of 0.05. Infants who
had high levels of Bifidobacterium at month 4 had a significantly lower abundance of
reads belonging to class tetracycline than infants who had low levels of Bifidobacterium
at month 4 when comparing infant microbiomes at month 12 (Kruskal-Wallis test,
FIG 5 Relative abundance of Bifidobacterium of Swedish infants at month 4. (A) Bifidobacterium relative abundance in all month 4 samples. (B) Bifidobacterium
relative abundance at month 4 in only samples included in the AMR analysis. The empty space at the start of bar charts in panels A and B is for the 6 samples
that had no or almost no Bifidobacterium present. (C) Bifidobacterium levels at year 1; samples are in the same order as panel A and are color coded by
Bifidobacterium levels at month 4. (D) Plot showing the year 1 samples from only infants classified as either high or low Bifidobacterium at month 4; these were
the infants included in the year 1 analyses.
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P 0.00116), despite an increase in tetracycline abundance in the high-Bifidobacterium
samples between months 4 and 12 (Wilcoxon paired test, P 0.0312) and a decrease
in tetracycline abundance in the low-Bifidobacterium samples between months 4 and
12 (Wilcoxon paired test, P 0.0465) (Fig. 8). Only the two mechanisms that differed
significantly at 4 months were tested at 12 months, with a Bonferroni-corrected P value
for significance of 0.025. There was no significant difference in the mechanism class A
beta-lactamases (P 0.159); however, month 4 low-Bifidobacterium infants had a sig-
nificantly higher abundance of the mechanism tetracycline resistance ribosomal pro-
tection proteins than month 4 high-Bifidobacterium infants (P 0.0001).
FIG 6 Total ARG reads normalized by read length and 16S read count at month 4 in the Swedish infants.
There was no significant difference in total ARG abundance between high- and low-Bifidobacterium
infants (Kruskal-Wallis test, P 0.0613). P value for significance is 0.05.
FIG 7 Total ARG abundance at year 1 in the Swedish cohort. Samples from infants with low Bifidobac-
terium at month 4 had significantly more ARG abundance than samples from infants who had high
Bifidobacterium at month 4 (Kruskal-Wallis test, P 0.0105). P value for significance is 0.05.
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Comparing levels of AMR in infants at month 4 with those in infants at month 12,
high-Bifidobacterium infants did not have significantly different abundances of total
AMR (P 0.156, Wilcoxon paired test). However, as with the Bangladeshi cohort,
low-Bifidobacterium early-life infants did experience a significant drop in the abundance
of AMR between month 4 and month 12 (P 0.0001, Wilcoxon paired test) (Fig. 9).
FIG 8 Normalized abundance of tetracycline resistance genes in Swedish infants by AMR. High-
Bifidobacterium infants had significantly less tetracycline resistance at both month 4 (P 0.000310,
Kruskal-Wallis test) and year 1 (P 0.00116, Kruskal-Wallis test). This is despite an increase in tetracycline
resistance in the high-Bifidobacterium infants (P 0.0312, Wilcoxon paired test) and a decrease in
tetracycline resistance in the low-Bifidobacterium infants (P 0.00116, Wilcoxon paired test). As tetracy-
cline was the only class of AMR to meet the P value of 0.00294 for significance, it was the only class
compared at the later time points. This means that comparisons using the year 1 data had a P value of
0.05 for significance.
FIG 9 AMR normalized total ARG abundance over time. Comparison between month 4 and year 1
AMR levels in the Swedish cohort. There was no significant difference in AMR abundance between the
month 4 and year 1 high-Bifidobacterium samples (P 0.156, Wilcoxon paired test). There was a
significant decrease in AMR abundance between the month 4 and year 1 low-Bifidobacterium samples
(P 0.0001, Wilcoxon paired test). Significance was determined using a P value of 0.05.
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DISCUSSION
AMR is a major public health challenge, and the gut microbiome may come to
harbor ARGs even in the first few days of life (28, 29). Globally, there are an estimated
214,000 neonatal sepsis deaths each year attributable to AMR pathogens (39). In
particular, resistance to the first-line antibiotics for sepsis, penicillin-ampicillin with
gentamicin, is present in as many as 35% of older infants with sepsis and resistance to
second-line cephalosporins is also common (40). In early life, Bifidobacterium at levels
greater than 65% correlates strongly with reduced levels of ARGs, in terms of both a
reduced diversity of transferable ARGs present and reduced ARG abundance in the
Bangladeshi infants. The relative abundance differences in Bifidobacterium do correlate
with differences in absolute abundance of Bifidobacterium by qPCR. In addition, the
high-Bifidobacterium infants had lower levels of total bacteria and of family Enterobac-
teriaceae than the low-Bifidobacterium infants. Despite being the most common pre-
dicted origin of AMR, levels of family Enterobacteriaceae measured by qPCR did not
correlate with a reduction in total AMR abundance in early life. This may be related to
the small sample size of this analysis (only 28 samples had sufficient DNA for qPCR).
That there was a significant correlation between Bifidobacterium and a reduction in
total AMR abundance suggests that Bifidobacterium may suppress more AMR-carrying
taxa than just Enterobacteriaceae. This is consistent with past research that finds that
Bifidobacterium has an inhibitory effect on the growth of a variety of other commensals,
including pathogens, via organic acid (particularly acetate) and bacteriocin production
(41–43). This potentially keeps niches that might otherwise be occupied by AMR-
containing organisms open until weaning. In the Swedish infants, there was a trend
toward a significant reduction in ARGs in the high-Bifidobacterium infants (P 0.06). A
key difference is that in the Swedish cohort the typical relative abundance of Bifido-
bacterium in early life was much lower, resulting in very few infants in the high category
for the comparisons. However, a regression model testing for the association between
total ARG abundance and Bifidobacterium level using all infants in the Swedish cohort
did find a significant association, where higher levels of Bifidobacterium correlated with
lower levels of total ARG abundance. This suggests that infants with gut microbiomes
dominated by Bifidobacterium are at lower risk of AMR-associated diseases, although
additional studies are needed to confirm this hypothesis.
Historically, the infant microbiome was dominated by Bifidobacterium (44, 45).
However, by the 1970s in the United States, urban infants were beginning to exhibit a
drop in Bifidobacterium levels in infant stool (46). Others have previously noted differ-
ential distribution of Bifidobacterium within neonates from different locations (8),
suggesting that this benefit of AMR reduction by high early Bifidobacterium may be
regional. Bifidobacterium is linked to a variety of beneficial health effects, including
immunological modulations (9, 47) and improvement in barrier function (48, 49),
among others. A recent intervention study showed that a high level of Bifidobacterium
from supplementation with B. longum subsp. infantis correlates with lower fecal endo-
toxin (5). The high level of Bifidobacterium present in this Bangladeshi cohort was
previously associated with improved vaccine response (9), and follow-on work has
recently demonstrated that high early Bifidobacterium (in this case primarily B. longum
subsp. infantis) correlates with improved vaccine responses at 2 years (M. N. Huda, S. M.
Ahmad, M. J. Alam, A. Khanam, K. M. Kalanetra, D. H. Taft, R. Raqib, M. A. Underwood,
D. A. Mills, and C. B. Stephensen, submitted for publication).
Of particular importance, high Bifidobacterium levels are associated with reduced
beta-lactam resistance in early-life samples in Bangladesh. Beta-lactams such as amoxi-
cillin are the first-line antimicrobials for acute otitis media (50). Importantly, high levels
of Bifidobacterium also correlated with reduced transferable beta-lactam resistance in
this cohort. In the Bangladeshi infants, the median level of transferable beta-lactam
resistance was 55 times greater during early life in low-Bifidobacterium infants than in
high-Bifidobacterium infants. While in the Swedish infants there was not a significant
association between the abundance of all beta-lactams and Bifidobacterium levels,
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there was an association between reduced levels of class A beta-lactamases and high
Bifidobacterium levels. This suggests that a microbiome dominated by Bifidobacterium
not only has the potential to help protect infants at high risk of sepsis from disease caused
by an AMR-bearing microorganisms generally but also that high Bifidobacterium levels may
lower the level of the ARGs most likely to cause problems during treatment of sepsis.
Supplementing breastfed infants with probiotics to dominate the gut with Bifidobacterium
is experimentally possible; a recent study established that supplementing healthy breastfed
term infants with Bifidobacterium in early life was well tolerated (4) and resulted in
dramatically greater levels of Bifidobacterium in infant stool than those for nonsupple-
mented infants (5). This strategy may prove particularly effective in reducing AMR in
populations where infants do not naturally acquire high levels of Bifidobacterium.
While high bifidobacterial levels correlated with reduced AMR during early life, there
were mixed results in the effect of Bifidobacterium levels in the later-life samples. In the
Bangladeshi samples, there was no association between early-life Bifidobacterium levels
and AMR at age 2 years. Furthermore, the number of different transferable AMR classes
and ARGs increased in the high-Bifidobacterium infants, despite no change in AMR
abundance. The number of different transferable AMR classes and ARGs did not change
in the low-Bifidobacterium infants. Together, this suggests that high levels of Bifidobac-
terium delayed the acquisition of ARGs and that the increasing levels of bacteria diluted
the abundance of ARGs at later time points. In the Swedish cohort at year 1, the month
4 low-Bifidobacterium infants had significantly higher levels of ARGs than the month 4
high-Bifidobacterium infants. These same infants had a persistent reduction in tetracy-
cline resistance levels at month 12 if they had high levels of Bifidobacterium at month
4. This may also reflect the shorter time period to acquire additional ARGs available to
the Swedish cohort than the Bangladeshi cohort. In both the Bangladeshi infants and
the Swedish infants, AMR abundance did not change significantly between early-life
and later-life samples in infants with high levels of Bifidobacterium in early life. However,
infants in both cohorts with low levels of early-life Bifidobacterium experienced a
significant drop in AMR abundance between early-life and later samples. The discrep-
ancy between the Bangladeshi and Swedish infants in whether high Bifidobacterium in
early life is associated with a sustained reduction in at least one class of AMR highlights
the need for more research into the biogeography and timing of infant colonization by
AMR-carrying organisms. This study is limited by the availability of samples at different
time points for inclusion; only a single early-life sample and a single sample from year
1 (Swedish infants) or from year 2 (Bangladeshi infants) were available, and the earlier
timing of the Swedish samples may explain the discrepancy in whether differences in
later-life total ARG abundance could be detected by early-life Bifidobacterium levels.
The limited time points of collection in both the Swedish and Bangladeshi cohorts do
not provide the data needed to fully describe the trajectory of AMR colonization in
these infants or to explore how other environmental factors affect AMR coloniza-
tion. An additional limitation of this study is a lack of data on antimicrobial use in
the Bangladeshi cohort. It is possible that the infants with low Bifidobacterium
received antimicrobials, which may drive an increase in AMR in the microbiome. To
fully understand the relationship between Bifidobacterium dominance in infancy
and AMR levels in early life, studies with dense sampling during infancy and
childhood including infants from both developed and developing countries are
needed to first understand how stability or fluctuations of Bifidobacterium domi-
nance affect AMR levels and then to understand how far into the weaning process
and under what environmental conditions a reduction in AMR associated with early
high levels of Bifidobacterium may extend.
MATERIALS AND METHODS
Bangladeshi cohort. This study used samples collected from infants enrolled in a clinical trial of
vitamin A supplementation and vaccine effectiveness (ClinicalTrials.gov NCT01583972) and a follow-up
study on Bifidobacterium levels in early infancy and vaccine response in early infancy and at age 2 years
(NTC02027610) (26; M. N. Huda, S. M. Ahmad, M. J. Alam, A. Khanam, K. M. Kalanetra, D. H. Taft, R. Raqib,
M. A. Underwood, D. A. Mills, and C. B. Stephensen, submitted for publication). Ethical approval was
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obtained from the Research Review Committee and the Ethical Review Committee of the International
Centre for Diarrheal Disease Research, Bangladesh. Stool samples were collected from 291 infants at age
weeks 6, 11, and 15, and 250 of these infants also provided a sample at age 2 years. The 16S rRNA gene
sequencing was completed as described in the work of Huda et al. (9), and results were processed using
the QIIME2 DADA2 pipeline (51, 52). These results were used to select infants low in Bifidobacterium
(20% relative abundance) or high in Bifidobacterium (65% relative abundance) in early life (age week
6, 11, or 15) for whole metagenomics sequencing. Only a single early-life sample per infant was included.
The high prevalence of Bifidobacterium dominance of the gut microbiota in this cohort resulted in a
limited number of low-Bifidobacterium samples available for inclusion. In addition, reliable information on
whether infants received antimicrobial agents was unavailable and so could not be included in analysis.
DNA extraction and whole-metagenomics sequencing. DNA was extracted as described in the
work of Huda et al. (9) and sent to the UC Berkeley Functional Genomics Laboratory for library
preparation and subsequent Illumina sequencing at the UC Berkeley Genomics Sequencing Laboratory.
Prior to sequencing, each sample was sheared using the 150-bp setting of the Diagenode Bioruptor and
then purified and concentrated with the Qiagen MinElute cleanup kit. End repair, A tailing of DNA fragments,
and adapter ligation were performed using the Kapa Hyper Prep library kit. Next, 9 cycles of indexing PCR
were performed using the Kapa Hi-Fi HotStart amplification kit. Cleanup and dual-solid phase reversible
immobilization (SPRI) size selection were completed using AMPure beads. Libraries were checked for quality
on the AATI fragment analyzer (Advanced Analytical Technologies, Inc.), quantified with Kapa Illumina Library
quantitative PCR on a Bio-Rad CFX Connect, and pooled in equimolar amounts. Sequencing was completed
at 3 nM using the Illumina HiSeq4000 with 150-bp paired-end reads. Bcl files were converted to demultiplexed
FastQ file format using the Illumina bcl2fastq v2.18 software.
Samples were sequenced in three separate sequencing runs. The first two runs consisted of a mix of high-
and low-Bifidobacterium samples from early life, while the third run contained the samples from year 2.
Analysis of antimicrobial resistance genes. Organisms may have intrinsic, adaptive, or acquired
AMR (53). Intrinsic resistance refers to inherent characteristics of the organism that result in resistance to
an antimicrobial agent: for example, the outer membrane of Gram-negative organisms prevents agents
from reaching their targets (53). Importantly, intrinsic resistance is not usually horizontally transferable
(54). Adaptive resistance is when an organism can rapidly turn on a gene in response to environmental
cues (53). Unlike intrinsic or acquired resistance, adaptive resistance will usually revert when the
environmental trigger is removed (55). Acquired resistance is when a previously sensitive organism gains
resistance to an antimicrobial agent either through new mutations or through acquisition of ARGs from
other organisms (53). Acquired resistance is particularly problematic, as part of the problem with carriage
of AMR organisms is that ARGs can transfer between both closely and distantly related taxa (56), and
many of the resistance genes found in commensal human gut flora are identical at the nucleotide level
to resistance genes in human pathogens (57). The differences in importance between intrinsic and
acquired AMR have led to the creation of databases with different focuses. For example, the ResFinder
database focuses exclusively on acquired resistance genes (58), while the MEGARes database includes
both intrinsic and acquired AMR (36). Despite this ubiquity of ARGs in bacteria, not all bacteria carry ARGs
in general, or acquired ARGs specifically, at comparable levels.
Prior to analyzing reads with ResFinder or MEGARes, host subtraction was completed on each sample
using BMTagger in BMTools v. 1 (59) and the GRCh38 build of the human genome. Reads were trimmed
using Trimmomatic v. 0.36 with a sliding window of 4 bp, a minimum average quality of 15, and a
minimum length of 99 bp. Paired-end reads were then merged using FLASH v 1.2.11 (60). The trimmed
reads where both ends survived trimming were then assembled using MEGAHIT v. 1.0.6 (61), and the
resulting final contigs were uploaded to ResFinder 3.0 (58) to identify the presence or absence of
acquired ARGs. Contigs were not filtered by length because ARGs may be found on plasmids and
plasmids may be as small as 1 kb (62). The numbers of unique ARGs present in high- and low-
Bifidobacterium infants in early life were compared in R 3.4.3 statistical software (63) using Kruskal-Wallis
tests for both early-life and year 2 samples. The number of unique ARGs present in the early-life high-
and low-Bifidobacterium samples was then divided by the number of reads in the sample to account for
the differences in read depth observed in the early-life samples, and numbers were compared using
Kruskal-Wallis tests. To test if differences in ARGs in early life may be related to differences in delivery
mode, a stratified analysis was completed comparing ARG counts by delivery mode in high- and
low-Bifidobacterium infants. The assembled contigs identified as containing an ARG by ResFinder were
compared with the NCBI nucleotide collection (nr/nt) (33) using a custom BLAST script (https://github
.com/akre96/ResistBlast) to identify themost probable taxon of origin for each ARG. For each ARG, the contig
containing the ARG was run through NCBI BLAST, and the top three species hits with at least 90% identity
match were returned. As ResFinder is focused on transferable ARGs which can be shared across taxa, the
family of each of the top three hits was identified. If all three hits were from the same family, the ARG was
considered to originate in that family. If the top three hits originated from two or more families, the origin or
the ARG was considered mixed. If ResistBlast returned no hits or if all hits were to uncultured bacterium, the
family of origin was considered to be unknown. The percentage of ARGs in each sample mapping to each
origin was calculated by dividing the number of ARGs mapping to a particular origin in each sample, dividing
by the total number of ARGs in that sample, and multiplying by 100.
Next, the FLASH merged reads were analyzed using AMR (resistomeanalyzer v. 1) and the
MEGARes v 1.01 database using default settings (36) to determine the total number of reads
mapping to ARGs. To normalize the number of AMR reads, the merged reads were analyzed using
METAXA2 v. 2.1.3 (64) to count the number of reads mapping to bacterial 16S rRNA genes. The
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normalized abundance of ARGs was then calculated for each sample as described in the work of Li
et al. (35) using the formula
Abundance
1
n NAMR Lreads ⁄ LAMRref
N16S Lreads ⁄ 1,432
where n is each individual ARG in the MEGARes database, N(AMR) is the number of reads mapping to
ARGs according to AMR, L(reads) is the length of the sequencing reads and cancels out of the
equation because the length is the same for both the AMR reads and the 16S reads, L(AMRref) is the
length of the AMR reference gene in the MEGARes database, N(16S) is the number of reads mapping to 16S
rRNA gene bacterial reads by METAXA2, and 1,432 is the average length of a 16S rRNA gene sequence in the
Greengenes database. Differences in total AMR abundance between high- and low-Bifidobacterium infants in
early life were tested in both early-life samples using the Kruskal-Wallis test in R (63). An advantage of the
MEGARes database is its acyclic classification of ARGs into groups, mechanisms, and classes. We were then
able to test for differences between high- and low-Bifidobacterium infants in ARG abundance at the gene,
group, mechanism, and class levels of the MEGARes database using a Bonferroni correction for multiple
comparisons at each level and Kruskal-Wallis tests. As with the ResFinder analysis, a stratified analysis
(stratified by Bifidobacterium level) was used to test for an association between AMR levels and delivery mode
in early life. To confirm the results of the early-life Bangladeshi comparison, FLASH merged reads were also
processed using ShortBRED (37) using default settings and the 2017 CARD marker gene database prebuilt by
the authors.
Sequencing results from year 2 samples were processed in the same manner as early-life samples
for the ResFinder analysis. For the abundance analysis, only the classes, mechanisms, groups, and
genes significantly different in early-life samples were compared in later-life samples to determine
if any differences in AMR in early life are maintained at later time points. Early-life and year 2 total
abundances of AMR were then compared using a Wilcoxon paired test.
Total bacteria, total Bifidobacterium, and total Enterobacteriaceae quantification. Quantitative
PCR (qPCR) was conducted to determine the absolute abundance of total bacteria and total Bifidobac-
terium. Briefly, DNA extracted from stool was diluted 1:10 before use. The standard curves for qPCR were
generated using a 10-fold dilution series of DNA extracted from Escherichia coli sldp 38-1 (total bacteria)
or Bifidobacterium longum subsp. infantis ATCC 15697 (total Bifidobacterium) in liquid cultures at late
exponential phase for which cell numbers were determined by quantitative culture. Total bacterial qPCR
was completed using a melting temperature (Tm) of 60°C using the 27F (5=AGAGTTTGATCCTGGCTCAG3=)
and 355R (5=CTGCTGCCTCCCGTAGGAGT3=) primers described by Cariveau et al. (65). Total Bifidobac-
terium qPCR was completed using a Tm of 58°C using the genus Bifidobacterium F (5=TCGCGTC[C/T
]GGTGTGAAAG3=) and genus Bifidobacterium R (5=CCACATCCAGC[A/G]TCCAC3=) primers described
by Krumbeck et al. (66). Total Enterobacteriaceae qPCR was completed using a Tm of 56°C using the
family Enterobacteriaceae F (5=CATTGACGTTACCCGCAGAAGAAGC3=) and family Enterobacteriaceae R
(5=CTCTACGAGACTCAAGCTTGC3=) primers as described by Oh et al. (67). Total abundances of
bacteria, total abundances of Bifidobacterium, and total abundances of Enterobacteriaceae were
compared between the high- and low-Bifidobacterium groups using a Kruskal-Wallis test. The
correlation between early-life bacterial abundance (total, Bifidobacterium, and Enterobacteriaceae)
and normalized total AMR abundance (from AMR) was calculated using Spearman’s test.
Early-life and year 2 total bacteria and total Bifidobacterium levels were stratified by Bifidobacterium
level, and only infants with both an early-life and a year 2 sample were included for statistical testing
using a Wilcoxon paired test.
Swedish cohort. To confirm findings in the Bangladeshi cohort in an unrelated cohort, samples
from the study by Bäckhed et al. (30) of the human gut microbiome in Swedish infants during the
first year of life were downloaded from EBI’s Sequence Read Archive under the accession code
ERP005989. Briefly, this cohort enrolled 100 mother-infant dyads and used WGS to examine the
development of the infant microbiome from birth until age 12 months. For this study, the infant month
4 and month 12 samples were included. After downloading the month 4 and 12 sequencing files, data
were processed using AMR, which includes a normalization step to adjust for differences in read
depth, with the same criteria as the Bangladeshi cohort except that the FLASH merge step was skipped
due to a longer insert size. As samples were sequenced without selection based on Bifidobacterium levels,
correlation between read depth and Bifidobacterium relative abundance was tested using Spearman’s
correlation test at both months 4 and 12. Then, regression using the log-transformed total AMR was
completed in R 3.4.3 using the glm command and including the number of times that infants that were
exposed to antibiotics before age 4 months and the relative abundance of Bifidobacterium in the month
4 samples as predictor variables. Then, to more directly compare results of the two cohorts, samples were
classified as high or low Bifidobacterium using the METAXA2 results on the month 4 samples using the
same criteria as for the 16S rRNA gene sequencing on the Bangladeshi cohort. The abundances of AMR
in the month 4 and month 12 samples were calculated using the AMR pipeline as described above.
Accession number(s). Host subtracted data are available on the NCBI SRA under accession number
SRP133760.
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